ATE425253T1 - Tribonektine - Google Patents

Tribonektine

Info

Publication number
ATE425253T1
ATE425253T1 AT00926303T AT00926303T ATE425253T1 AT E425253 T1 ATE425253 T1 AT E425253T1 AT 00926303 T AT00926303 T AT 00926303T AT 00926303 T AT00926303 T AT 00926303T AT E425253 T1 ATE425253 T1 AT E425253T1
Authority
AT
Austria
Prior art keywords
tribonectins
tribosupplementation
tribonectin
injured
administering
Prior art date
Application number
AT00926303T
Other languages
English (en)
Inventor
Gregory Jay
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23152784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE425253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of ATE425253T1 publication Critical patent/ATE425253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Conductive Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00926303T 1999-04-23 2000-04-24 Tribonektine ATE425253T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/298,970 US6743774B1 (en) 1999-04-23 1999-04-23 Tribonectins

Publications (1)

Publication Number Publication Date
ATE425253T1 true ATE425253T1 (de) 2009-03-15

Family

ID=23152784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00926303T ATE425253T1 (de) 1999-04-23 2000-04-24 Tribonektine

Country Status (9)

Country Link
US (6) US6743774B1 (de)
EP (1) EP1173567B2 (de)
JP (5) JP2003500022A (de)
AT (1) ATE425253T1 (de)
AU (1) AU781564B2 (de)
CA (1) CA2367750C (de)
DE (1) DE60041761D1 (de)
ES (1) ES2324199T5 (de)
WO (1) WO2000064930A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
WO2001058958A1 (en) * 2000-02-09 2001-08-16 Glaxo Group Limited Antibody binding superficial zone protein and their uses in diagnosis and screening methods
GB0003092D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
EP1347993A2 (de) * 2000-12-29 2003-10-01 Glaxo Group Limited Das "superficial zone protein" und verfahren zu dessen herstellung und anwendung
EP1401481A1 (de) * 2001-06-14 2004-03-31 Novo Nordisk A/S Schleimhautreparatur mit tff-dimer-peptiden
US20060240037A1 (en) * 2003-06-04 2006-10-26 Edward Fey Methods and compositions for the treatment and prevention of degenerative joint disorders
WO2005016130A2 (en) * 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
WO2005102363A2 (en) * 2004-04-20 2005-11-03 Mucosal Therapeutics Llc Methods of promoting cartilage healing or cartilage integration
US20080287369A1 (en) * 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
EP1827478A4 (de) * 2004-12-03 2009-08-05 Mucosal Therapeutics Llc Verfahren zur behandlung von verletzten oder erkrankten gelenken
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US20090298761A1 (en) * 2006-05-17 2009-12-03 Donald Engelman Methods of treating cartilage defects using a soluble morphogenic protein complex
US20090068247A1 (en) * 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
HRP20150097T1 (hr) 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka
ES2534082T3 (es) 2009-01-13 2015-04-17 Lubris Llc Modulación terapéutica de la lubricación del límite del epitelio vaginal
TW201031412A (en) * 2009-01-29 2010-09-01 Riken Combined preparation for treating joint diseases
WO2010135736A2 (en) * 2009-05-22 2010-11-25 Singularis Inc. Application and uses of prg4 and therapeutic modulation thereof
WO2011091000A2 (en) 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
US20130116186A1 (en) * 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
WO2014115022A1 (en) 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
US9982027B2 (en) * 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US10500250B2 (en) 2013-11-26 2019-12-10 Lubris Llc Compositions and methods for inhibiting intercellular interactions
AU2016211694B2 (en) 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
LT3300482T (lt) 2015-05-19 2021-10-25 Lubris Llc Prg4 panaudojimas dinaminio regos aštrumo pagerinimui ir aukštesnės eilės aberacijų sumažinimui
MX381665B (es) * 2016-01-13 2025-03-13 Genzyme Corp Star Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
US11137407B2 (en) 2016-02-23 2021-10-05 Lynxon Ab Method of diagnosing arthritis or other joint degrading disease
KR20220145361A (ko) 2020-02-24 2022-10-28 노파르티스 아게 재조합적으로 생성된 폴리펩타이드의 정제
JP7063369B2 (ja) * 2020-12-07 2022-05-09 株式会社三洋物産 遊技機
US20250282981A1 (en) 2022-04-27 2025-09-11 Lubris Llc Methods of making polymer films

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734862A (en) 1956-02-14 Synthetic casein fiber elastic grease
US2487377A (en) 1948-04-17 1949-11-08 Socony Vacuum Oil Co Inc Lubricant
US2878184A (en) 1953-12-29 1959-03-17 Rockwell Mfg Co Hydrocarbon resistant glycerol base lubricant
AR207237A1 (es) 1974-02-25 1976-09-22 Thomas A Procedimiento para obtener extractos biologicos estables liofilizados solubles constituidos por complejos proteicos termorresistentes
US4438100A (en) 1980-04-25 1984-03-20 A/S Orthana Kemisk Fabrik Sterilized preserved, stable mucine-containing solutions
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5260417A (en) 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) † 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
AU652022B2 (en) 1991-02-12 1994-08-11 C.R. Bard Inc. Injectable medical device
JPH04278061A (ja) 1991-03-05 1992-10-02 Suntory Ltd 栄養食品
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5709020A (en) 1994-07-19 1998-01-20 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5515590A (en) 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5510122A (en) 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
FR2726188B1 (fr) * 1994-11-02 1996-12-20 Inst Vaisseaux Et Du Sang Composition glycosaminoglycane/facteur de croissance megacaryocytaire, utilisation en therapeutique
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
AT405477B (de) 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
WO1998018491A1 (en) 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
JP2004517030A (ja) 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
US6291533B1 (en) 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
GB0003092D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
EP1347993A2 (de) 2000-12-29 2003-10-01 Glaxo Group Limited Das "superficial zone protein" und verfahren zu dessen herstellung und anwendung
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
GB2381750A (en) 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030224386A1 (en) 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005016130A2 (en) 2003-08-14 2005-02-24 Wyeth Recombinant lubricin molecules and uses thereof
CA2558497A1 (en) 2004-03-05 2005-09-15 Synthes (U.S.A.) Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
US20080287369A1 (en) 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin

Also Published As

Publication number Publication date
US20100204087A1 (en) 2010-08-12
EP1173567B1 (de) 2009-03-11
WO2000064930A3 (en) 2001-01-25
EP1173567B2 (de) 2012-10-31
EP1173567A2 (de) 2002-01-23
JP2016041769A (ja) 2016-03-31
JP2012070738A (ja) 2012-04-12
CA2367750A1 (en) 2000-11-02
US20040229804A1 (en) 2004-11-18
US20100048458A1 (en) 2010-02-25
US20140179611A1 (en) 2014-06-26
US8680057B2 (en) 2014-03-25
JP5909592B2 (ja) 2016-04-26
CA2367750C (en) 2013-10-22
US6743774B1 (en) 2004-06-01
ES2324199T3 (es) 2009-08-03
JP2014144015A (ja) 2014-08-14
AU4485200A (en) 2000-11-10
AU781564B2 (en) 2005-06-02
US8026346B2 (en) 2011-09-27
DE60041761D1 (de) 2009-04-23
US20130072435A1 (en) 2013-03-21
JP2003500022A (ja) 2003-01-07
WO2000064930A2 (en) 2000-11-02
JP2016172760A (ja) 2016-09-29
ES2324199T5 (es) 2013-03-20
US7618941B2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
DE60041761D1 (de) Tribonektine
DE69925133D1 (de) Pyrrolobenzodiazepine
ATE264863T1 (de) 28-epirapaloge
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
NO974554L (no) FremgangsmÕte for behandling av en underjordisk formasjon
DE69929418D1 (de) Implantierbare medizinische vorrichtung
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
PT1032396E (pt) Esterilizacao de glucocorticoesteroides
IT1285770B1 (it) Composti corticoidei
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
FI935779L (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
EA200100930A1 (ru) Способ лечения хозл
ES2186807T3 (es) Inhibidores de trombina.
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
BG100248A (bg) Инхибитори на скваленсинтетаза
NO20005548L (no) Mykobakterieinhibitorer
EA200101106A1 (ru) Фармацевтический комплекс
HRP20050611A2 (en) Combination medicament

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties